^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

1772 / 1 - EGFR signaling as a mechanism of resistance to CDK4/6 inhibitors in Palbociclib-resistant ER+ breast cancer cells

Published date:
03/09/2022
Excerpt:
We evaluated the expression and activity of EGFR in two different matching pairs of ER+ palbociclib-sensitive (pS) and palbociclib-resistant (pR) breast cancer cell lines (MCF7 and T47D) and observed elevated EGFR expression in MCF7/pR cells.